表紙
市場調查報告書

生物相似藥市場趨勢 (2019年)

Biosimilar Market Trends 2019

出版商 Kalorama Information 商品編碼 876843
出版日期 內容資訊 英文 83 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
生物相似藥市場趨勢 (2019年) Biosimilar Market Trends 2019
出版日期: 2019年05月07日內容資訊: 英文 83 Pages
簡介

本報告提供全球生物相似藥的市場調查,市場定義和概要,各地區的市場規模的變化、預測,主要企業的市場佔有率,專利已失效、專利預計失效的主要生物醫藥品,各地區的生物相似藥的核准趨勢,相關法律、指南,其他的課題、趨勢等彙整資料。

第1章 摘要整理

  • 概要
  • 調查範圍、調查手法
  • 市場規模、成長率
    • 全球市場的預測
    • 市場影響因素
    • 市場展望

第2章 簡介、概要

  • 生物相似藥:概要
  • 市場趨勢
    • 歐洲
    • 美國
    • 其他地區
  • 產業領導者

第3章 專利失效生物醫藥品的生物相似藥醫藥品

第4章 專利預計失效生物醫藥品的生物相似藥醫藥品

第5章 生物相似藥市場趨勢

  • 市場摘要
  • 發展趨勢
    • 生物相似藥的核准趨勢:各產品、地區
    • 競爭分析
  • 歐洲和生物相似藥
    • 核准趨勢
    • 市場預測
  • 美國和生物相似藥
    • 核准趨勢
    • 市場預測
  • 其他地區和生物相似藥
    • 概要
    • 日本
    • 印度
    • 中國
    • 韓國
    • 澳洲

第6章 法律規章、專利

  • 概要
    • EU指南
    • 美國指南
    • 兼容性
    • 專利、專利舞蹈的課題

第7章 其他的課題、趨勢

  • 供應商的教育
  • 開關的疑慮
  • 創新者的策略、課題
  • 償付上的課題
  • 生物相似藥的命名、標籤檢視
目錄
Product Code: 19-095

Biopharmaceuticals are synthetic or recombinant versions of natural biologic substances, including proteins such as enzymes or antibodies, and nucleic acids such as DNA or RNA. Generic products are non-patented chemical and therapeutic equivalents of brand name drugs. However, biosimilars are not generic biologics because there can be no generic form of biologics due to the complex process of creating biologics. “Biosimilar Market Trends 2019” is designed to provide a snapshot of issues and trends that are affecting the biosimilar market today, along with the various strategies being used by both innovator companies and generic companies in the developing world of biosimilars.

Market data on the global opportunity for biosimilars provided include:

  • Global Biosimilar Market Opportunity, 2019-2024 ($ Millions)
  • Biosimilar Competitor Analysis, Estimated 2019 (% Global Market Share)
  • European Union Biosimilar Market, 2019-2024 ($ millions)
  • United States Biosimilar Market, 2019-2024 ($ millions)
  • Global Biosimilar Market Opportunity by Region, 2019-2024 ($ Millions) (European Union, United States, Rest of World, Global Biosimilar Market)
  • Rest of World Biosimilar Market, 2019-2024 ($ millions)
  • Global Biosimilar Market Growth by Region, 2019-2024 (%) (European Union, United States, Rest of World)

The issues and trends surrounding the prescription biosimilars pharmaceutical market are many but, as the pharmaceutical industry has experienced in the past, the generics industry is tough, resilient and determined. The generics industry has managed to overcome obstacles and prevail. It is expected that with due diligence, the generics industry will not only break into the biotechnology market but create formidable competition for brand biotech companies and reap substantial profits. However, the report does note several issues that will first need to be addressed, including:

  • Legislative Issues and Guidelines
  • Interchangeability
  • Patent and Patent Dance Issues
  • Provider Education
  • Switching Concerns
  • Innovator Strategies and Challenges
  • Reimbursement Issues
  • Biosimilar Naming and Labeling

Kalorama has identified the biopharmaceuticals that have lost patent protection and are the first products to reach the market. Some of these products are relatively simple in structure (by biotech complexity) such as the insulins and human growth hormones, while others are extremely difficult to process. Kalorama also has identified biopharmaceuticals for future expired biologic patents.

Biosimilar market data provided include:

  • Select Marketed Biologics with Expired Patents
  • Select Marketed Biologics with Active Patents

The development of the global market for biosimilars presents an opportunity for cost savings and improved health outcomes. Despite the benefits, the market has been slow to develop and is only a fraction of its potential. The path to making biosimilars as common as traditional generic drugs has historically been a slow and agonizing process for all involved; but there are some major industry changes in the past couple years that have extended the market, improved regulatory processes and brought more biological options to health professionals and patients around the world. The report provides the following information on the current state of biosimilar development by regional market:

  • Biosimilar Approval by Product and Region (Biologic, Product/Innovator, United States, European Union, Japan, Canada, China, South Korea, Australia)
  • Biosimilar Approvals by Region (United States, European Union, Japan, Canada, China, South Korea, Australia)
  • Biosimilars Approved in EU (Biosimilar Name, Manufacturer, Reference Drug, Approval Date)
  • Biosimilar Competitor Activity: European Union (Number of Approvals by Biologic)
  • Biosimilars Approved in United States (Biosimilar Name, Manufacturer, Reference Drug, Approval Date)
  • Biosimilar Competitor Activity: United States (Number of Approvals by Biologic)
  • Biosimilars Approved in Japan (Biosimilar Name, Manufacturer, Reference Drug, Approval Date)
  • Biosimilar Competitor Activity: Japan (Number of Approvals by Biologic)
  • Selected Biosimilars Approved in India (Biosimilar Name, Manufacturer, Reference Drug, Approval Date)
  • Biosimilar Competitor Activity: China (Number of Approvals by Biologic)
  • Biosimilars Approved in South Korea (Biosimilar Name, Manufacturer, Reference Drug, Approval Date)
  • Biosimilar Competitor Activity: South Korea (Number of Approvals by Biologic)
  • Biosimilars Approved in Australia (Biosimilar Name, Manufacturer, Reference Drug, Approval Date)
  • Biosimilar Competitor Activity: Australia (Number of Approvals by Biologic)

“Biosimilar Market Trends 2019” examines as well legislative and patent issues. Global biosimilars are continuing to grow worldwide with emerging regions playing a larger role. As demonstrated by analysis of various countries, many emerging markets are establishing biosimilar regulatory pathways, providing increasing opportunities for biosimilar development. However, there are still regulatory and operational hurdles to address. Uniform clinical studies remain an issue and harmonization between country regulations is still concerning. Guidelines in many emerging countries are patterned after European Medicines Agency (EMA) guidelines, which is helping to provide some semblance of comparable harmonization in requirements.

Issues discussed in the report include:

  • EU Guidelines
  • US Guidelines
  • Interchangeability
  • Patent and Patent Dance Issues

For the purposes of this study, Kalorama has focused on the market for products which have lost patent protection in key markets. Projections were made based on the progress that is occurring within the generic arena in terms of capabilities, capital, interest, and development of biopharmaceuticals. The information and analysis presented in this report are based on an extensive survey of senior management in the biosimilar drug industry. Background information was obtained from a comprehensive search of published literature and reports obtained from various government, business, medical trade, and international journals. Key information from published literature was used to conduct interviews with industry executives and product managers to validate and obtain expert opinion on current and future trends in the biosimilar industry. Interviews were also used to confirm and/or adjust market size, as well as in formulating market projections.

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

  • OVERVIEW
  • SCOPE AND METHODOLOGY
  • SIZE AND GROWTH OF THE MARKET
    • The Global Market for Biosimilars
      • Table 1-1: Global Biosimilar Market Opportunity, 2019-2024 ($ Millions)
      • Figure 1-1: Global Biosimilar Market Opportunity, 2019-2024 ($ Millions)
    • Trends Affecting the Market
    • Market Outlook

2. INTRODUCTION AND OVERVIEW

  • BIOSIMILARS OVERVIEW
    • Table 2-1: Scientific Differences of Pharmaceuticals and Biopharmaceuticals
  • WHAT'S BEEN GOING ON IN THE MARKET?
    • Europe
    • US
    • Rest of World
  • INDUSTRY LEADERS

3. BIOSIMILAR PHARMACEUTICALS FOR EXPIRED BIOLOGIC PATENTS

  • Table 3-1: Select Marketed Biologics with Expired Patents

4. BIOSIMILAR PHARMACEUTICALS FOR FUTURE EXPIRED BIOLOGIC PATENTS

  • Table 4-1: Select Marketed Biologics with Active Patents

5. BIOSIMILAR MARKET ACTIVITY

  • MARKET SUMMARY
    • Table 5-1: Global Biosimilar Market Opportunity by Region, 2019-2024 ($ Millions) (European Union, United States, Rest of World, Global Biosimilar Market)
    • Figure 5-1: Global Biosimilar Market Growth by Region, 2019-2024 (%) (European Union, United States, Rest of World)
  • DEVELOPMENT OVERVIEW
    • Table 5-2: Biosimilar Approval by Product and Region (Biologic, Product/Innovator, United States, European Union, Japan, Canada, China, South Korea, Australia)
    • Figure 5-2: Biosimilar Approvals by Region (United States, European Union, Japan, Canada, China, South Korea, Australia)
  • Competitor Analysis
    • Figure 5-3: Biosimilar Competitor Analysis, Estimated 2019 (% Global Market Share)
  • EUROPE AND BIOSIMILARS
    • Table 5-3: Biosimilars Approved in EU (Biosimilar Name, Manufacturer, Reference Drug, Approval Date)
    • Figure 5-4: Biosimilar Competitor Activity: European Union (Number of Approvals by Biologic)
  • European Union Biosimilar Market Overview
    • Table 5-4: European Union Biosimilar Market, 2019-2024 ($ millions)
    • Figure 5-5: European Union Biosimilar Market, 2019-2024 ($ millions)
  • UNITED STATES AND BIOSIMILARS
    • Table 5-5: Biosimilars Approved in United States (Biosimilar Name, Manufacturer, Reference Drug, Approval Date)
    • Figure 5-6: Biosimilar Competitor Activity: United States (Number of Approvals by Biologic)
  • United States Biosimilar Market Overview
    • Table 5-6: United States Biosimilar Market, 2019-2024 ($ millions)
    • Figure 5-7: United States Biosimilar Market, 2019-2024 ($ millions)
  • REST OF WORLD AND BIOSIMILARS
    • Rest of World Biosimilar Market Overview
      • Table 5-7: Rest of World Biosimilar Market, 2019-2024 ($ millions)
      • Figure 5-8: Rest of World Biosimilar Market, 2019-2024 ($ millions)
    • Japan
      • Table 5-8: Biosimilars Approved in Japan (Biosimilar Name, Manufacturer, Reference Drug, Approval Date)
      • Figure 5-9: Biosimilar Competitor Activity: Japan (Number of Approvals by Biologic)
    • India
      • Table 5-9: Selected Biosimilars Approved in India (Biosimilar Name, Manufacturer, Reference Drug, Approval Date)
    • China
      • Figure 5-10: Biosimilar Competitor Activity: China (Number of Approvals by Biologic)
    • South Korea
      • Table 5-10: Biosimilars Approved in South Korea (Biosimilar Name, Manufacturer, Reference Drug, Approval Date)
      • Figure 5-11: Biosimilar Competitor Activity: South Korea (Number of Approvals by Biologic)
    • Australia
      • Table 5-11: Biosimilars Approved in Australia (Biosimilar Name, Manufacturer, Reference Drug, Approval Date)
      • Figure 5-12: Biosimilar Competitor Activity: Australia (Number of Approvals by Biologic)

LEGISLATIVE AND PATENT ISSUES

  • OVERVIEW
    • EU Guidelines
    • US Guidelines
    • Interchangeability
    • Patent and Patent Dance Issues
      • Table 6-1: Selected Patent Litigation Activity (Innovator, Biosimilar Company, Product, Status)

7. OTHER INDUSTRY ISSUES AND TRENDS

  • PROVIDER EDUCATION
  • SWITCHING CONCERNS
  • INNOVATOR STRATEGIES AND CHALLENGES
  • REIMBURSEMENT ISSUES
  • BIOSIMILAR NAMING AND LABELING
Back to Top